Enrolling by invitationPhase 3NCT06679946

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Studying Amyloidosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Alnylam Pharmaceuticals
Principal Investigator
Medical Director
Alnylam Pharmaceuticals
Intervention
Vutrisiran(drug)
Enrollment
700 enrolled
Eligibility
18 years · All sexes
Timeline
20242028

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06679946 on ClinicalTrials.gov

Other trials for Amyloidosis

Additional recruiting or active studies for the same condition.

See all trials for Amyloidosis

← Back to all trials